Update to IAS-USA drug resistance tables

The IAS-USA 2022 Update of the Drug Resistance Mutations in HIV-1 is now available in early e-publication.

The 2022 edition covers the following drugs.

  • Cabotegravir, fostemsavir and ibalizumab are all now included. The capsid inhibitor lenacapavir (GS 6207) has been added to Figure 2.
  • A new section on recently approved drugs.
  • Several changes were made to the bars of the integrase strand transfer inhibitors (InSTIs) cabotegravir and dolutegravir, the protease inhibitors atazanavir and lopinavir, and the nonnucleoside analogue reverse transcriptase (NNRTI) inhibitor doravirine.
  • The user notes for tenofovir have been modified as recent clinical data suggest that the K65R plus M184V mutational profile is of less clinical relevance if tenofovir with either lamivudine or emtricitabine is prescribed in combination with a boosted protease inhibitor or one of the second generation InSTIs bictegravir or dolutegravir.
  • Antiretroviral drugs that are no longer recommended are listed at the bottom of the drug class and are shaded in gray. Their user notes are retained for historical significance.

This article will be published in Issue 30, Volume 4, of Topics in Antiviral Medicine. (PDF)

Links to other websites are current at date of posting but not maintained.